HILE(SH:603718) Xin Lang Zheng Quan·2026-02-26 01:19Group 1 - The core viewpoint of the news is that Haili Biological has shown a mixed performance in terms of financing and stockholder metrics, with a notable decrease in revenue but a slight increase in net profit [1][2]. Group 2 - As of February 25, Haili Biological's stock price increased by 0.20%, with a trading volume of 79.57 million yuan [1]. - The financing data indicates that on February 25, Haili Biological had a financing buy amount of 3.51 million yuan and a financing repayment of 6.67 million yuan, resulting in a net financing buy of -3.16 million yuan [1]. - The total balance of margin trading for Haili Biological as of February 25 is 145 million yuan, which accounts for 4.48% of its market capitalization, indicating a low level compared to the past year [1]. - On the same day, Haili Biological had no shares repaid in short selling, with 6,000 shares sold short, amounting to 29,900 yuan at the closing price [1]. - The short selling balance is 203,700 yuan, which is also low compared to the 20% percentile level over the past year [1]. Group 3 - As of September 30, Haili Biological had 33,800 shareholders, an increase of 7.16% from the previous period, while the average circulating shares per person decreased by 6.68% to 19,196 shares [2]. - For the period from January to September 2025, Haili Biological reported a revenue of 150 million yuan, a year-on-year decrease of 14.15%, while the net profit attributable to shareholders was 20.33 million yuan, reflecting a year-on-year increase of 0.77% [2]. - Since its A-share listing, Haili Biological has distributed a total of 209 million yuan in dividends, with 107 million yuan distributed over the past three years [2]. - As of September 30, 2025, the fifth largest circulating shareholder of Haili Biological is the Guotai Zhongzheng Livestock Breeding ETF, holding 10.23 million shares, an increase of 3.70 million shares from the previous period [2].